Susquehanna International Group, LLP Cure Vac N.V. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.74 - $3.79 $142,480 - $197,080	52,000 Added 307.69%	68,900 $202,000
Q2 2024 Aug 15, 2024	SELL	$2.31 - $4.99 $29,568 - $63,872	-12,800 Reduced 43.1%	16,900 $57,000
Q1 2024 May 07, 2024	SELL	$2.94 - $4.34 $21,756 - $32,116	-7,400 Reduced 19.95%	29,700 $89,000
Q4 2023 Feb 14, 2024	SELL	$3.96 - $6.41 $150,084 - $242,939	-37,900 Reduced 50.53%	37,100 $156,000
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $22,750 - $37,695	3,500 Added 4.9%	75,000 $512,000
Q2 2023 Aug 11, 2023	BUY	$6.69 - $12.25 $70,245 - $128,625	10,500 Added 17.21%	71,500 $745,000
Q1 2023 May 16, 2023	BUY	$6.38 - $12.5 $308,154 - $603,750	48,300 Added 380.31%	61,000 $425,000
Q4 2022 Feb 14, 2023	SELL	$5.75 - $8.5 $397,325 - $587,350	-69,100 Reduced 84.47%	12,700 $76,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $1.42 Million - $2.89 Million	-189,400 Reduced 69.84%	81,800 $645,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $585M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.